SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics -- Ignore unavailable to you. Want to Upgrade?


To: End2War who wrote (1167)9/16/2025 1:06:09 PM
From: End2War3 Recommendations

Recommended By
bobbseytwins2001
erippetoe
Olecranon

  Respond to of 1216
 

Dr. Pat Soon-Shiong




@DrPatSoonShiong

·
23h

To be clear these patients with complete responses in Waldenstrom did not undergo the standard of care lymphodepletion..,meaning the trial we are running is entirely chemo free
@cssifm
. The patients are receiving our targeted NK cell therapy and Anktiva plus a targeted Antibody